GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Change In Other Working Capital

CMPX (Compass Therapeutics) Change In Other Working Capital : $-0.95 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Compass Therapeutics Change In Other Working Capital?

Compass Therapeutics's Change In Other Working Capital for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Compass Therapeutics's Other Working Capital increased by $0.00 Mil from Jun. 2024 to Sep. 2024 .

Compass Therapeutics's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $-1.20 Mil. It means Compass Therapeutics's Other Working Capital declined by $1.20 Mil from Dec. 2022 to Dec. 2023 .

Compass Therapeutics Change In Other Working Capital Historical Data

The historical data trend for Compass Therapeutics's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Therapeutics Change In Other Working Capital Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial -0.10 -0.29 -1.11 -1.10 -1.20

Compass Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.31 -0.32 -0.33 -

Compass Therapeutics Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Compass Therapeutics's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Change In Other Working Capital
Comparable Companies
CELC XOMA FULC EPIX DRTS ARQT YMAB IGMS HUMA ZURA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
80 Guest Street, Suite 601, Boston, MA, USA, 02135
Website
https://www.compasstherapeutics.com
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
Executives
Richard S Lindahl director NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Thomas J. Schuetz director, officer: Chief Executive Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
David M Wurzer director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Vered Bisker-leib officer: Chief Operating Officer C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Ellen Chiniara director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Philip Ferneau director 10 ALLEN STREET, HANOVER NH 03755
Orbimed Capital Gp V Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Susan Kalled officer: Chief Scientific Officer COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135
Brett Kaplan director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016